International Journal of Molecular Sciences · 2020 · 24 citations · 36 references
Life SciencesImmunologyOncologyCancer ImmunologyCell TherapyImmunotherapyAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyHuman Leukocyte Antigen SystemHybridoma TechnologyT Cell BiologyB-cell LeukemiaCar T Cell TrialsCar-nk Cell TherapyChimeric Antigen Receptor DesignChimeric Antigen Receptor T Cell ManufacturingSingle-chain Variable Fragment ConstructionSingle-chain Variable Fragment LibrariesSingle-chain Variable Fragments
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-CD19 CAR T cells use FMC63 single-chain variable fragments (scFvs) for binding CD19 expressed on the cancer cell surface. In this study, we screened several known CD19 scFvs for developing anti-CD19 CAR T cells. We used the KHYG-1 NK/T-cell line for screening of CD19 scFvs because it has advantages in terms of cell culture and gene transduction compared to primary T cells. Using our CAR construct backbone, we made anti-CD19 CAR constructs which each had CD19 scFvs including FMC63, B43, 25C1, BLY3, 4G7, HD37, HB12a, and HB12b, then made each anti-CD19 CAR KHYG-1 cells. Interestingly, only FMC63 CAR KHYG-1 and 4G7 CAR KHYG-1 efficiently lysed CD19-positive cell lines. In addition, in Jurkat cell line, only these two CAR Jurkat cell lines secreted IL-2 when co-cultured with CD19-positive cell line, NALM-6. Based on these results, we made FMC63 CAR T cells and 4G7 CAR T cells from PBMC. In in vitro lysis assay, 4G7 CAR T cells lysed CD19-positive cell line as well as FMC63 CAR T cells. In in vivo assay with NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice, 4G7 CAR T cells eradicated NALM-6 as potently as FMC63 CAR T cells. Therefore, we anticipate that 4G7 CAR T cells will show as good a result as FMC63 CAR T cells for B-cell leukemia patients.
36
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park, Isabelle Rivière, Mithat Gönen et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text
Life Sciences, Hematology, Oncology +17
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Javier Muñoz, André Goy et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text
Medicine, Hematology, Oncology +15